Tuesday, Feb 19 2019 | Time 01:42 Hrs(IST)
  • Shiv Sena agreed for alliance with BJP fearing ED probe: Vikhe Patil
  • Iraq: 1 killed, 7 kidnapped by IS
  • Foreign jihadists should be judged in the region: Belgian PM
  • At least 10 Houthi rebels killed in clashes with Yemeni gov't forces
  • Bihar: Major reshuffle of IPS officers ahead of LS election
  • After BJP-Shiv Sena alliance in Mah, Cong wonders whether it is 'grand adultration' or 'grand fear'
  • Indian diplomat Mittal declines 'handshake' offer from Pak Attorney General at ICJ
  • Be confident: MP CM to students
Business Economy Share

Strides enters into strategic partnership with SUDA Pharmaceuticals for US market

Strides enters into strategic partnership with SUDA Pharmaceuticals for US market

Mumbai, Nov 09(UNI) Pharma Strides Pharma Science Limited today said that its step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals Ltd (ASX: SUD) for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.

Execution of Strides' generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway., company said in afiling with BSE.

The company through inhouse development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period. Today's announcement of partnership with SUDA is part of company's specialty portfolio buildout for the US market.

Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults. SUD-001H is a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand name Imitrex).

The product will be filed with the USFDA under the 505B (2) regulatory pathway and on approval is expected to be the first fast-acting oral spray of sumatriptan in the US market. The product will utilize SUDA's recently developed proprietary OroMist® hydrotrope technology that significantly improves the rate of absorption and the quantity of drug that is absorbed across the mucosal membranes. A primary market assessment on the potential for SUD-001H for the treatment of adult migraine confirmed the need for a product that could demonstrate a faster onset of action and the same was supported by medical practitioners.

Under terms of the agreement SUDA will provide product development services for SUD-001H funded by Strides SUDA to work with Strides team through joint committees to achieve successful USFDA approval for the product SUDA to receive an upfront cash payment of US$ 0.4 Mn and a further payment of US$ 0.6 Mn on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the US.On commercial sales, SUDA will receive royalties plus a handling fee

Strides to have a right of first refusal for additional territories including the European Union, Australia and New Zealand, Canada, South Africa and Japan.

UNI JS SY 1219

More News

Emami Group promoters divest 10 pc stake for INR 1600 cr in Emami Limited

18 Feb 2019 | 8:40 PM

Kolkata, Feb 18 (UNI) The promoters of Emami Group today announced a sale
of 10 per cent stake in Emami Limited, raising approximately INR 1600 crores.

 Sharesee more..

Cognizant named Top Employer 2019 in Europe, Asia-Pacific and Latin America

18 Feb 2019 | 7:32 PM

Teaneck, New Zersey, Feb 18 (UNI) Cognizant has been certified a Top Employer for 2019 in Australia, Brazil and Singapore, as well as across ten European countries: Belgium, France, Germany, Lithuania, Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.

 Sharesee more..

Benelli's launches much-awaited Adventure Tourer TRK 502 & TRK 502X

18 Feb 2019 | 7:13 PM

Kolkata, Feb 18 (UNI) Benelli, a leading worldwide manufacturer of premium bikes and
Adishwar Auto Ride India – Mahavir Group, today launched the adventure-oriented
range “Benelli TRK 502”and “Benelli TRK 502X”.

 Sharesee more..
RBI to transfer interim surplus of Rs 28,000 cr to Govt

RBI to transfer interim surplus of Rs 28,000 cr to Govt

18 Feb 2019 | 6:48 PM

New Delhi, Feb 18 (UNI) The Reserve Bank of India Board on Monday decided to transfer an interim surplus of Rs 28,000 crore to the Government for the half year ended December 31, 2018.

 Sharesee more..
Govt working to double steel production to 300 MT by 2031: Singh

Govt working to double steel production to 300 MT by 2031: Singh

18 Feb 2019 | 6:25 PM

New Delhi, Feb 18 (UNI) Union Steel Minister Chaudhary Birender Singh on Monday said the Government is hoping to double the capacity and take steel production to 300 million tonnes by 2031 under the National Steel Policy 2017.

 Sharesee more..